Related Experiment Video
Updated: Jan 13, 2026

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
Published on: August 19, 2021
Isolation, functional characterization and antibiofilm properties of a lytic Enterococcus phage RG1 against multidrug
Rakesh Kumar Singh1, Riya Anand1, Ajeet Singh1
1Zoology Section, Mahila Mahavidyalaya, Banaras Hindu University, Varanasi, 221005, India.
Abstract:
Enterococcus faecium, a multidrug-resistant (MDR), commensal human pathogen, frequently causes nosocomial infections and imposes serious threat to public health, which demanded more research for the development of alternative therapeutics against them. Bacteriophage therapy as an alternative to antibiotics has reappeared as therapeutics against MDR bacterial infections. Here, we isolated and characterized a novel lytic phage, RG1, from the Ganga River against E. faecium ATCC 35667 and checked their efficacy against several clinical isolates of E. faecium. Whole genome sequencing revealed that the RG1 belongs to genus Efemquintavirus, and has a dsDNA genome of 41,364 base pairs with 35.54% GC content, which encodes 65 putative open reading frames without any virulence, antibiotic resistance or lysogeny genes. Bacteriophage RG1 displayed high stability across different pH, temperatures and chloroform concentrations. The phage RG1 exhibited antibacterial and antibiofilm activity over both ATCC and clinical isolates of E. faecium likely due to its wider host range, which paves the way inside the precision phage therapy. Interestingly, the presence of ribose, maltose and trehalose sugars showed more suppression of bacterial growth of MDR E. faecium isolate in presence of the phage RG1, while sugar alcohols synergistically supported host lysis by this phage. These findings highlight the therapeutic potential of the phage RG1 against the MDR E. faecium under clinical setup.
Insights
A novel lytic bacteriophage, RG1, was isolated from the Ganga River to combat multidrug-resistant Enterococcus faecium infections. This phage demonstrates broad-spectrum antibacterial and antibiofilm activity, offering a promising alternative therapeutic strategy.
Area of Science:
- Microbiology
- Molecular Biology
- Biotechnology
Background:
- Enterococcus faecium is a multidrug-resistant pathogen causing significant nosocomial infections.
- The rise of antibiotic resistance necessitates the development of alternative therapeutics.
- Bacteriophage therapy is emerging as a viable alternative to antibiotics.
Purpose of the Study:
- To isolate and characterize a novel lytic bacteriophage effective against multidrug-resistant Enterococcus faecium.
- To evaluate the therapeutic potential of the isolated phage against clinical isolates of E. faecium.
- To investigate the phage's stability and host range for potential precision phage therapy.
Main Methods:
- Isolation and characterization of a lytic bacteriophage (RG1) from the Ganga River against E. faecium.
- Whole genome sequencing of the bacteriophage RG1.
- Assessment of phage stability across various pH, temperature, and chloroform concentrations.
- Evaluation of antibacterial and antibiofilm activity against E. faecium isolates.
- Investigation of synergistic effects of sugars and sugar alcohols on phage efficacy.
Main Results:
- RG1, a novel lytic phage belonging to the Efemquintavirus genus, was identified.
- The phage possesses a dsDNA genome encoding 65 open reading frames, with no identified virulence, antibiotic resistance, or lysogeny genes.
- RG1 demonstrated high stability and broad-spectrum antibacterial and antibiofilm activity against E. faecium.
- Specific sugars (ribose, maltose, trehalose) suppressed bacterial growth, while sugar alcohols enhanced phage-mediated lysis.
Conclusions:
- Bacteriophage RG1 exhibits significant therapeutic potential against multidrug-resistant Enterococcus faecium.
- The phage's stability, broad host range, and synergistic interactions with certain compounds support its application in precision phage therapy.
- RG1 represents a promising alternative therapeutic agent for combating nosocomial E. faecium infections.
Related Concept Videos
Development of Antibiotic Resistance
Lytic Cycle of Bacteriophages
Viral Replication: Lytic Cycle
Gene Regulation in Microbial Communities: Quorum Sensing
Antimicrobial Effectiveness

